These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24142143)

  • 61. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Onuzo OC
    Cardiol Young; 2004 Aug; 14(4):466-7; author reply 467-9. PubMed ID: 15680062
    [No Abstract]   [Full Text] [Related]  

  • 62. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Recommendations for immunologic prevention of respiratory syncytial virus (RSV) infections].
    Z Geburtshilfe Neonatol; 1999 Dec; 203 Suppl 2():16. PubMed ID: 10612193
    [No Abstract]   [Full Text] [Related]  

  • 64. Respiratory syncytial virus trials and beyond.
    Mazur NI; van Delden JJ; Bont LJ
    Lancet Infect Dis; 2015 Dec; 15(12):1363-5. PubMed ID: 26511957
    [No Abstract]   [Full Text] [Related]  

  • 65. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 66. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against.
    Isaacs D
    Paediatr Respir Rev; 2013 Jun; 14(2):128-9. PubMed ID: 23422687
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prevention of respiratory syncytial virus infection in infants.
    Handforth J; Sharland M; Friedland JS
    BMJ; 2004 May; 328(7447):1026-7. PubMed ID: 15117767
    [No Abstract]   [Full Text] [Related]  

  • 68. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States.
    Krilov LR; Palazzi DL; Fernandes AW; Klein RW; Mahadevia PJ
    Value Health; 2010; 13(1):77-86. PubMed ID: 19706010
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prevention of respiratory syncytial viral infections in late preterm infants.
    Sankaran K; Kalappurackal M; Tan B
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Apr; 15(4):241-8. PubMed ID: 23607943
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.
    Handal G; Logvinoff MM; Zegarra N; Allen L; Jesurun A; Levin G; Thida A
    Tex Med; 2000 May; 96(5):58-61. PubMed ID: 10843015
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Palivizumab prophylaxis in preterm infants.
    Tang PK
    Lancet Respir Med; 2017 Mar; 5(3):171. PubMed ID: 28219614
    [No Abstract]   [Full Text] [Related]  

  • 74. New perspectives in Respiratory Syncitial Virus infection.
    Del Vecchio A; Ferrara T; Maglione M; Capasso L; Raimondi F
    J Matern Fetal Neonatal Med; 2013 Oct; 26 Suppl 2():55-9. PubMed ID: 24059554
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA; Rao P; Brandon-Cox C
    J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [RSV-prophylaxis--to whom?].
    Lossius K
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2494. PubMed ID: 11070982
    [No Abstract]   [Full Text] [Related]  

  • 78. A review of cost-effectiveness of palivizumab for respiratory syncytial virus.
    Hussman JM; Li A; Paes B; Lanctôt KL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):553-67. PubMed ID: 23140255
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.
    Smart KA; Lanctôt KL; Paes BA
    Can Fam Physician; 2010 Oct; 56(10):988-91. PubMed ID: 20944037
    [No Abstract]   [Full Text] [Related]  

  • 80. Re: technical report.
    Braden NJ
    Pediatrics; 2014 Dec; 134(6):e1781. PubMed ID: 25452649
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.